257 related articles for article (PubMed ID: 26713053)
1. Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.
Yan C; Kim YH; Kang HW; Seo SP; Jeong P; Lee IS; Kim D; Kim JM; Choi YH; Moon SK; Yun SJ; Kim WJ
J Korean Med Sci; 2015 Dec; 30(12):1784-92. PubMed ID: 26713053
[TBL] [Abstract][Full Text] [Related]
2. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH.
Yun SJ; Yan C; Jeong P; Kang HW; Kim YH; Kim EA; Lee OJ; Kim WT; Moon SK; Kim IY; Choi YH; Kim WJ
Ann Surg Oncol; 2015 Jul; 22(7):2439-45. PubMed ID: 25348783
[TBL] [Abstract][Full Text] [Related]
3. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
4. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
[TBL] [Abstract][Full Text] [Related]
5. Detection of miRNAs in urine of prostate cancer patients.
Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
[TBL] [Abstract][Full Text] [Related]
6. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
7. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
8. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
[TBL] [Abstract][Full Text] [Related]
9. Molecular Diagnostic of Prostate Cancer From Body Fluids Using Methylation-Specific PCR (MS-PCR) Method.
Minciu R; Dumache R; Gheorghe P; Daminescu L; Rogobete AF; Ionescu D
Clin Lab; 2016; 62(6):1183-6. PubMed ID: 27468582
[TBL] [Abstract][Full Text] [Related]
10. [Detection of urine DD3/PSA mRNA ratio by duplex TaqMan RT-PCR assay and evolution of its primary application].
Chen FP; Chen LL; Shen M; Chen W; Tao ZH; Wu XL; Hu YP; Li CD; Chen ZG; Chen XD
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):261-4. PubMed ID: 18361839
[TBL] [Abstract][Full Text] [Related]
11. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
[TBL] [Abstract][Full Text] [Related]
12. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
[TBL] [Abstract][Full Text] [Related]
13. The utility of urine-circulating miRNAs for detection of prostate cancer.
Stuopelyte K; Daniunaite K; Bakavicius A; Lazutka JR; Jankevicius F; Jarmalaite S
Br J Cancer; 2016 Sep; 115(6):707-15. PubMed ID: 27490805
[TBL] [Abstract][Full Text] [Related]
14. Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer.
Byun YJ; Piao XM; Jeong P; Kang HW; Seo SP; Moon SK; Lee JY; Choi YH; Lee HY; Kim WT; Lee SC; Cha EJ; Yun SJ; Kim WJ
Investig Clin Urol; 2021 May; 62(3):340-348. PubMed ID: 33834642
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers.
Ma W; Diep K; Fritsche HA; Shore N; Albitar M
Genet Test Mol Biomarkers; 2014 Mar; 18(3):156-63. PubMed ID: 24512523
[TBL] [Abstract][Full Text] [Related]
16. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
[TBL] [Abstract][Full Text] [Related]
17. Screening, identification of prostate cancer urinary biomarkers and verification of important spots.
Zhao H; Zhao X; Lei T; Zhang M
Invest New Drugs; 2019 Oct; 37(5):935-947. PubMed ID: 30610587
[TBL] [Abstract][Full Text] [Related]
18. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
19. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
Zhong W; Peng J; He H; Wu D; Han Z; Bi X; Dai Q
Clin Invest Med; 2008; 31(1):E8-E15. PubMed ID: 18312749
[TBL] [Abstract][Full Text] [Related]
20. A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples.
Guo J; Yang J; Zhang X; Feng X; Zhang H; Chen L; Johnson H; Persson JL; Xiao K
Anticancer Res; 2018 Mar; 38(3):1471-1477. PubMed ID: 29491074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
